Myelodysplastic Syndrome (MDS) Drugs Market Growth Analysis, Production Overview, Advanced Share, Competitive Analysis and Industry Forecast to 2025
Market Highlights:
The Global Myelodysplastic
Syndrome (MDS) Drugs Market is expected to grow significantly over the
forecast period. The Myelodysplastic Syndrome (MDS) drugs market held a
valuation of USD 1,581.59 million in 2018 and is
projected to register a CAGR of 10.1% over the forecast period.
The increasing participation of key
players is one of the key factors driving the Myelodysplastic Syndrome (MDS)
drugs market. In 2018, the US Food and Drug
Administration approved generic injectable product decitabine for Lupin Ltd.
There are various other MDS medications available in the market.
Various other factors that are driving
the MDS drugs market are the promotion of clinical studies related to MDS,
increasing geriatric population, rise in regulatory approvals, and growing
participation of generic drugs manufactures.
However, the risk of infections during
blood transfusions and side-effects of chemotherapy may hamper market growth
over the forecast period.
Access Report Details and Full
TOC Exclusively @ https://www.marketresearchfuture.com/reports/myelodysplastic-syndrome-drugs-market-8134
Key Players:
·
BluePoint
Laboratories
·
Celgene
Corporation
·
Celgene
Europe Limited
·
Dr.
Reddy's Laboratories Inc
·
Johnson
& Johnson
·
Lupin Ltd
Corporation
·
Otsuka
America Pharmaceutical Inc
·
Sandoz
·
Shilpa
Medicare Limited
·
Sun
Pharmaceutical Industries
Segmentation:
·
The
global Myelodysplastic Syndrome (MDS) drugs market is segmented based on
product, type of syndrome, route of administration, end user, and region.
·
Based on
product, the global Myelodysplastic Syndrome (MDS) drugs market is further
segmented into chemotherapy, immunomodulatory drugs, and others. T
·
The MDS
drugs market at a global level is segmented on type of syndrome into refractory
cytopenia with multilineage dysplasia, refractory anemia, refractory anemia
with excess blasts, refractory anemia with ringed sideroblasts, refractory
cytopenia with multilineage dysplasia, and others.
·
Based on
the route of administration, the market is segmented into oral, parenteral, and
others. The MDS drugs available in the market are administered through
parenteral route, for instance, intravenous or subcutaneous. The parental route
has a quick effective after administration.
·
Based on
end user, the market is segmented into hospitals, clinics, ambulatory surgical
centers, and others.
Regional Analysis:
In the current scope of the study, the segments
mentioned above are covered into the four global regions, namely, the Americas,
Europe, Asia-Pacific, and the Middle East and Africa.
The global MDS drugs market in the Americas has
further been segmented into North America and South America, with the North
American market divided into the US and Canada.
The European global MDS drugs market has been
segmented into Western Europe and Eastern Europe. Western Europe has been
classified as Germany, France, the UK, Italy, Spain, and the rest of Western
Europe. The MDS drugs market in Asia-Pacific has been segmented into
Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The
global Myelodysplastic Syndrome drugs market in the Middle East & Africa
has been segmented into the Middle East and Africa.
About Market Research Future:
At Market Research Future (MRFR), we
enable our customers to unravel the complexity of various industries through
our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Comments
Post a Comment